首页> 外文期刊>Journal of opioid management >Presence of opioid safety initiatives, prescribing patterns for opioid and naloxone, and perceived barriers to prescribing naloxone: Cross-sectional survey results based on practice type, scope, and location
【24h】

Presence of opioid safety initiatives, prescribing patterns for opioid and naloxone, and perceived barriers to prescribing naloxone: Cross-sectional survey results based on practice type, scope, and location

机译:表述安全举措的存在,适用于阿片类药物和纳洛酮的规定模式,以及规定纳洛酮的感知障碍:基于实践类型,范围和位置的横截面调查结果

获取原文
获取原文并翻译 | 示例
           

摘要

Background and objectives: The opioid epidemic is a public health crisis in the United States (US) and is associated with devastating consequences, including opioid misuse and related overdose. In response to the opioid crisis, the US Department of Health and Human Services is advancing improved practices in pain management. Strategies to help mitigate opioid risks include physician safety programs, hospital- or practice-based initiatives, patient education, and harm reduction campaigns that include the use of naloxone. To date, little information is available regarding the use of these strategies among healthcare providers. A survey was conducted to identify the presence of opioid safety initiatives, prescribing patterns of opioids and naloxone, and perceived barriers to prescribing naloxone. The presence of these strategies was compared between different practice types (hospital-based/ academic vs. private practice), practice scope (chronic pain vs. “other”), and practice location (in the US vs. outside the US) Regarding “outside the US, ” the actual geographical distribution of those countries was not captured by respondents. Methods: A 13-question web-based anonymous cross-sectional survey was sent to members of the American Society of Regional Anesthesia and Pain Medicine and the Women in Pain Medicine online community via email and social media (Twitter and Facebook). Survey questions were designed to ascertain the presence of opioid safety initiatives, opioid and naloxone prescribing patterns, and perceived barriers to prescribing naloxone based on practice type (hospital-based/ academic vs. private practice), scope (chronic pain vs. “other”), and location (in the US vs. outside the US). Results: Opioid safety initiatives: The presence of physician safety initiatives was found to be statistically higher among hospital-based/academic practices. No statistical difference was found for hospital- or practice-based, patient education, or harm reduction initiatives for different practice types (hospital-based/academic vs. private practice). The presence of patient education initiatives is statistically higher for chronic pain providers versus others. No statistical difference was found for physician safety, hospital- or practice-based, or harm reduction initiatives among the different practice scopes (chronic pain vs. others). The presence of opioid safety initiatives is statistically higher in the US compared with outside the US Prescribing patterns for opioids: Hospital-based/academic practices are more likely to prescribe opioids to patients suspected of the following: illicit or nonmedical drug use, recently released from prison or correctional facility, in opioid detoxification, a mandatory medication treatment program, and/or a current methadone maintenance program, and those having difficulty accessing emergency medical services. Chronic pain providers are more likely to prescribe opioids to patients taking antidepressants compared with “other” providers. Other providers are more likely to prescribe opioids to patients suspected of the following: illicit or nonmedical drug use, recently released from prison or correctional facility, in opioid detoxification, in mandatory medication treatment programs, in current methadone maintenance programs, and patients having difficulty accessing emergency medical services. There is no difference in opioid prescribing patterns based on practice location. Prescribing pattern for naloxone: Chronic pain providers and providers in the US are more likely to prescribe/recommend naloxone and are more aware of a state’s medical board guidelines on naloxone prescribing. There is no statistical difference between practice types. Most providers, regardless of practice type, scope, or location, will coprescribe naloxone at a morphine milligram equivalent per day threshold of >50. Hospital-based/academic practices are more likely to prescribe naloxone to patients with opioid prescriptions and c
机译:背景和目标:类阿片流行病是美国的一场公共卫生危机,与毁灭性后果有关,包括类阿片滥用和相关过量。为了应对阿片危机,美国卫生和公共服务部正在推进疼痛管理方面的改进实践。帮助减轻阿片类药物风险的策略包括医生安全计划、基于医院或实践的计划、患者教育,以及包括使用纳洛酮在内的减少伤害运动。到目前为止,几乎没有关于医疗保健提供者使用这些策略的信息。进行了一项调查,以确定阿片类药物安全措施的存在,阿片类药物和纳洛酮的处方模式,以及对纳洛酮处方的感知障碍。在不同的执业类型(基于医院/学术与私人执业)、执业范围(慢性疼痛与“其他”)和执业地点(美国境内与境外)之间,对这些策略的存在进行了比较。关于“美国境外”,受访者没有捕捉到这些国家的实际地理分布。方法:通过电子邮件和社交媒体(Twitter和Facebook)向美国区域麻醉和疼痛医学学会的成员以及疼痛医学在线社区的女性发送一份13个问题的基于网络的匿名横断面调查。调查问题旨在确定阿片类药物安全措施的存在、阿片类药物和纳洛酮的处方模式,以及基于执业类型(医院/学术与私人执业)、范围(慢性疼痛与“其他”)和地点(美国境内与境外)的纳洛酮处方感知障碍。结果:阿片类药物安全倡议:在医院/学术实践中,医生安全倡议的存在在统计学上更高。对于不同的实践类型(基于医院/学术实践与私人实践),基于医院或实践、患者教育或减少伤害的举措没有发现统计差异。与其他人相比,慢性疼痛提供者的患者教育计划在统计学上更高。在不同的实践范围(慢性疼痛与其他疼痛)中,医生安全、基于医院或实践或减少伤害的措施没有发现统计学差异。与美国以外的阿片类药物处方模式相比,美国境内阿片类药物安全倡议的存在在统计学上更高:医院/学术机构更有可能向涉嫌以下情况的患者开出阿片类药物处方:非法或非医疗药物使用,最近从监狱或教养机构释放,在阿片类药物戒毒,强制药物治疗计划和/或当前美沙酮维持计划,以及难以获得紧急医疗服务的患者。与“其他”提供者相比,慢性疼痛提供者更有可能向服用抗抑郁药的患者开出阿片类药物。其他提供者更有可能向涉嫌以下情况的患者开具类阿片处方:非法或非医疗药物使用、最近从监狱或教养机构获释、类阿片戒毒、强制药物治疗计划、当前美沙酮维持计划,以及难以获得紧急医疗服务的患者。基于实践地点的阿片类药物处方模式没有差异。纳洛酮的处方模式:美国的慢性疼痛提供者和提供者更可能处方/推荐纳洛酮,并且更了解州医疗委员会关于纳洛酮处方的指南。不同的练习类型之间没有统计学差异。大多数提供者,无论执业类型、范围或地点如何,都会以每天吗啡毫克当量>50的阈值共同处方纳洛酮。医院/学术实践更有可能为阿片类处方和c类药物的患者开纳洛酮

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号